IFP Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-14
| Closed | -$1K | – | 3201 |
|
|
2020
Q3 | $1K | Sell |
14
-4,611
| -100% | -$191K | ﹤0.01% | 2772 |
|
|
2020
Q2 | $165K | Buy |
+4,625
| New | +$147K | 0.01% | 746 |
|
|
2018
Q4 | – | Sell |
-2,324
| Closed | -$61K | – | 3999 |
|
|
2018
Q3 | $61K | Buy |
2,324
+132
| +6% | +$3.57K | ﹤0.01% | 1787 |
|
|
2018
Q2 | $45K | Sell |
2,192
-239
| -10% | -$5.13K | ﹤0.01% | 1992 |
|
|
2018
Q1 | $34K | Hold |
2,431
| – | – | ﹤0.01% | 2043 |
|
|
2017
Q4 | $34K | Buy |
2,431
+72
| +3% | +$973 | ﹤0.01% | 2068 |
|
|
2017
Q3 | $44K | Sell |
2,359
-63
| -3% | -$1.05K | ﹤0.01% | 2070 |
|
|
2017
Q2 | $41K | Hold |
2,422
| – | – | ﹤0.01% | 2106 |
|
|
2017
Q1 | $32K | Sell |
2,422
-45
| -2% | -$705 | ﹤0.01% | 2205 |
|
|
2016
Q4 | $37K | Buy |
2,467
+340
| +16% | +$4.49K | ﹤0.01% | 2061 |
|
|
2016
Q3 | $25K | Sell |
2,127
-28
| -1% | -$329 | ﹤0.01% | 2281 |
|
|
2016
Q2 | $23K | Buy |
+2,155
| New | +$22.2K | ﹤0.01% | 2274 |
|
|
2016
Q1 | – | Sell |
-1,204
| Closed | -$18K | – | 3747 |
|
|
2015
Q4 | $18K | Buy |
+1,204
| New | +$20.1K | ﹤0.01% | 2237 |
|
IFP Advisors's MNTA Position: Q4 2020 in Review
IFP Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 14 shares — an estimated $1K sold.
IFP Advisors first reported a position in MNTA in Q4 2015 and held it in 13 quarters. The position peaked at $165K in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- IFP Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- IFP Advisors sold 14 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $1K.
- IFP Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2015 and held it in 13 quarters.
- IFP Advisors's Momenta Pharmaceuticals, Inc. position peaked at $165K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on IFP Advisors's 13F filing for Q4 2020, filed 25 Jan 2021.